Replies to post #279281 on Avid Bioservices Inc (CDMO)

[Protector]

jakeDM, you seem to be better informed then average. You are correct, b2gp1 is one of many that they chose to test. The patent will create a "priority date" for their case.

The ESMO results w/ b2gp1 as biomarker (of which b2gp1 as biomarker is a "joke" and they know it) did well and given the pd1 crowd only addresses about 30% of patients and the current theory is bavi plus pd1 makes the pd1 drugs "better"...

A good Joke, you have to give them that :)

After that they can tie the observation to one or more of the many other biomarkers that relates to their case and use the priority date (since the US is now in the first-to-file system).

I think the 'IL' levels will do better because we know that there is a direct relation between IL-10/IL-12 changes when Bavituximab is in the mix. Patients with High IL-10 and/or Low IL-12 may benefit more from Bavi as bavi decreases IL-10 (the immuno suppression unblocking part) and increases IL-12 (the so needed immuno-activation part) which will result in immune system activation which in turn will lead to cell damage repair/evac, tumour fighting and adaptive immune system activity against relapse.